Compare Amphastar Pharmaceuticals Inc (AMPH) vs DigitalOcean Holdings Inc (DOCN) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

DigitalOcean (DOCN) trades at $130.49, down 7.38% over the past 24 hours, amid a bearish technical signal. The company reported strong Q1 2026 earnings of $0.44 per share, beating expectations, and anticipates record Q2 2026 results with remaining performance obligations exceeding $800 million. Revenue grew to $901.43 million in 2025, with a net income margin of 24.97%, though valuation ratios remain elevated with a P/E of 57.23. Analyst consensus is bullish with a $174.80 price target.

Outlook remains positive due to accelerating AI-driven cloud demand and strong execution, but risks include high valuation multiples, negative shareholder equity, and competitive pressure from hyperscalers. The stock offers growth potential if AI adoption continues, yet investors should monitor debt levels and margin sustainability.